REVELATION BIOSCIENCES, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
REVB$4.11+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $10,700,331 | $6,499,018 |
| Prepaid expenses and other current assets | 111,297 | 66,699 |
| Total current assets | 10,811,628 | 6,565,717 |
| Property and equipment, net | 18,067 | 56,332 |
| Operating lease right-of-use asset | 722,288 | — |
| Other assets | 30,941 | — |
| Total assets | $11,582,924 | $6,622,049 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $577,501 | $783,621 |
| Accrued expenses | 1,397,644 | 1,130,046 |
| Operating lease liability | 23,013 | — |
| Total current liabilities | 1,998,158 | 1,913,667 |
| Operating lease liability, net of current portion | 723,771 | — |
| Total liabilities | 2,721,929 | 1,913,667 |
| Commitments and Contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024 and 1,583,969 and 43,526 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 1,584 | 44 |
| Additional paid-in-capital | 58,278,698 | 45,213,976 |
| Accumulated deficit | (49,419,287) | (40,505,638) |
| Total stockholders’ equity | 8,860,995 | 4,708,382 |
| Total liabilities and stockholders’ equity | $11,582,924 | $6,622,049 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.